ALCL
MCID: ANP001
MIFTS: 60

Anaplastic Large Cell Lymphoma (ALCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 38 12 53 59 55 15
Anaplastic Large-Cell Lymphoma 37 29
Alcl 53 59
Cd30 Positive Anaplastic Large Cell Lymphoma 59
Ki-1 Positive Anaplastic Large Cell Lymphoma 59
Ki-1+ Anaplastic Large Cell Lymphoma 73
Primary Systemic Alcl 59
Sacl 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
Orphanet 59 ORPHA98841
UMLS via Orphanet 74 C0206180
MESH via Orphanet 45 D017728
ICD10 via Orphanet 34 C84.6 C84.7
KEGG 37 H01601
UMLS 73 C0206180

Summaries for Anaplastic Large Cell Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as anaplastic large-cell lymphoma, is related to alk-positive anaplastic large cell lymphoma and primary cutaneous anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is LINC01013 (Long Intergenic Non-Protein Coding RNA 1013), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adcetris and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 34.0 ALK JAK3 MCL1 MUC1 NPM1 STAT3
2 primary cutaneous anaplastic large cell lymphoma 33.8 ALK GZMB MUC1 NPM1 PTPRC
3 lymphoma 32.2 ALK NPM1 PAX5 TNFRSF8
4 reticulosarcoma 31.6 ALK CLU GZMB MUC1 NPM1 PAX5
5 lymphomatoid papulosis 31.2 ALK GZMB NPM1
6 lymphoma, hodgkin, classic 30.8 ALK PAX5 PTPRC TNFSF8
7 peripheral t-cell lymphoma 30.8 ALK GZMB TNFRSF8
8 inflammatory myofibroblastic tumor 30.6 ALK NPM1 RNF213
9 histiocytosis 30.5 CSF1R PTPRC TNFRSF8
10 mycosis fungoides 30.4 CLU GZMB STAT3 TNFRSF8
11 composite lymphoma 30.0 GZMB PAX5
12 mantle cell lymphoma 29.9 MCL1 PAX5 PTPRC
13 leukemia, acute myeloid 29.7 CSF1R MCL1 NPM1 PTPRC STAT3
14 leukemia, chronic lymphocytic 29.4 MCL1 PAX5 PTPRC STAT3 TNFRSF8 TNFSF8
15 alk-negative anaplastic large cell lymphoma 12.8
16 anaplastic small cell lymphoma 11.8
17 b-cell lymphomas 10.4
18 autoimmune lymphoproliferative syndrome, type v 10.4
19 leukemia 10.4
20 hemophagocytic lymphohistiocytosis 10.3
21 adult t-cell leukemia 10.3
22 sarcoma 10.3
23 t-cell leukemia 10.3
24 diffuse large b-cell lymphoma 10.2
25 dermatitis 10.2
26 squamous cell carcinoma 10.2
27 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.2
28 eccrine porocarcinoma 10.2 MUC1 STAT3
29 conventional fibrosarcoma 10.2 PTPRC TNFRSF8
30 colon lymphoma 10.2 ALK PTPRC TNFRSF8
31 tenosynovial giant cell tumor 10.1 CLU CSF1R
32 human herpesvirus 8 10.1
33 arthritis 10.1
34 lymphocytic leukemia 10.1
35 panniculitis 10.1
36 acquired immunodeficiency syndrome 10.1
37 myeloid leukemia 10.1
38 soft tissue sarcoma 10.1
39 reticulum cell sarcoma 10.1 MUC1 PTPRC TNFRSF8
40 malignant leydig cell tumor 10.1 PAX5 TNFRSF8
41 lymphatic system cancer 10.1 ALK NPM1 PTPRC TNFRSF8
42 myeloid sarcoma 10.1 NPM1 PAX5 PTPRC
43 testicular infarct 10.1 PTPRC TNFRSF8
44 neuroblastoma 10.0
45 asthma 10.0
46 dermatitis herpetiformis, familial 10.0
47 dermatitis, atopic 10.0
48 burn scar 10.0
49 hematopoietic stem cell transplantation 10.0
50 ichthyosis 10.0

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CLU GZMB JUNB MCL1 TNFSF8 TRAF1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CLU GZMB JUNB MCL1 TNFSF8 TRAF1

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CSF1R IL9 JAK3 JUNB MCL1 NPM1
2 endocrine/exocrine gland MP:0005379 9.86 ALK CSF1R JAK3 MCL1 PTPRC RNF213
3 immune system MP:0005387 9.77 CLU CSF1R IL9 JAK3 JUNB MCL1
4 neoplasm MP:0002006 9.1 ALK JUNB NPM1 PAX5 PTPRC STAT3

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 394)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-22-7, 2068-78-2 5978
2
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
11
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
12
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
13
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
14
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
16
Vindesine Approved, Investigational Phase 4,Not Applicable 59917-39-4, 53643-48-4 40839
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
18
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
20
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
21
Crizotinib Approved Phase 4,Phase 1,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
22
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 51-75-2 4033
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
24
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 31703
25
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
26
Pirarubicin Investigational Phase 4 72496-41-4
27
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 0
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 358)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
4 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
5 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
7 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
13 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
14 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
15 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
16 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
21 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
22 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
23 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
24 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
26 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
29 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
30 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
31 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
32 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
33 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
34 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
35 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
36 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
37 CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Unknown status NCT02274584 Phase 1, Phase 2
38 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
39 Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
40 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
43 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2 SGN-30 (anti-CD30 mAb)
45 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed NCT00939770 Phase 1, Phase 2 Crizotinib
46 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed NCT00117988 Phase 2 tanespimycin
47 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Completed NCT01492088 Phase 1, Phase 2 Brentuximab vedotin
48 Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Completed NCT00099255 Phase 2 SGN-30
49 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed NCT00866047 Phase 2 brentuximab vedotin
50 Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Completed NCT02280785 Phase 2 Brentuximab vedotin

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

# Genetic test Affiliating Genes
1 Anaplastic Large-Cell Lymphoma 29

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

41
T Cells, Breast, Bone, B Cells, Bone Marrow, Nk Cells, Skin

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 1268)
# Title Authors Year
1
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. ( 29302678 )
2018
2
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )
2018
3
Improvement of cutaneous anaplastic large cell lymphoma by brentuximab vedotin monotherapy. ( 29391331 )
2018
4
Additional Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 29801080 )
2018
5
CD30-positive primary cutaneous anaplastic large cell lymphoma with coexistent pseudocarcinomatous hyperplasia. ( 29473196 )
2018
6
Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma. ( 29434148 )
2018
7
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. ( 29512859 )
2018
8
Response to "Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis". ( 29365059 )
2018
9
Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. ( 29445921 )
2018
10
Primary cutaneous anaplastic large-cell lymphoma: A case report. ( 29369180 )
2018
11
Characterization and diagnostic application of genomic <i>NPM-ALK</i> fusion sequences in anaplastic large-cell lymphoma. ( 29899875 )
2018
12
Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/I^-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. ( 29609590 )
2018
13
Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. ( 29921615 )
2018
14
Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed/refractory anaplastic large cell lymphoma. ( 29719098 )
2018
15
Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis. ( 29365043 )
2018
16
Is Latin America Ready to Identify Anaplastic Large Cell Lymphoma in Breast Implants Patients? Regional Encounter During the National Plastic Surgery Meeting in Cancun, Mexico. ( 29770862 )
2018
17
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. ( 29642597 )
2018
18
Lymphomatoid Papulosis (LyP) Associated with Diffuse Large B-cell Lymphoma and Cutaneous Anaplastic Large Cell Lymphoma: LyP as a Haematological Malignancy-related Dermadrome. ( 29796688 )
2018
19
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
20
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )
2018
21
<i>ALK</i>-Negative Anaplastic Large Cell Lymphoma Presenting as Disseminated Intravascular Coagulation and Hemophagocytic Lymphohistiocytosis: A Potentially Fatal Presentation. ( 29850298 )
2018
22
Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report. ( 29952979 )
2018
23
A 75-Year-Old Man with Progressive Generalized Erythroderma and History of Anaplastic Large Cell Lymphoma: Answer. ( 29286975 )
2018
24
Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. ( 29494757 )
2018
25
Reply to the Editor Regarding: Magnusson MR, Deva AK Letter to the Editor 2018 May 2 in Relation to: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesth Plast Surg, 2018. ( 29948093 )
2018
26
Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. ( 29302687 )
2018
27
Additional Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 29800972 )
2018
28
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. ( 29390984 )
2018
29
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the Spectrum of T-cell lymphomas with regulatory phenotype. ( 29898383 )
2018
30
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma. ( 29403168 )
2018
31
Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. ( 29370815 )
2018
32
Case of primary cutaneous anaplastic large cell lymphoma misdiagnosed as squamous cell carcinoma by pseudocarcinomatous hyperplasia. ( 29314194 )
2018
33
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). ( 29950528 )
2018
34
Primary Pulmonary Anaplastic Large Cell Lymphoma: A Rare Malignancy and Rare Cause of the Luftsichel Sign. ( 29854536 )
2018
35
Additional Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma-Reply. ( 29801121 )
2018
36
A Case of ALK+ Anaplastic Large-Cell Lymphoma With Aberrant Myeloperoxidase Expression and Initial Cutaneous Presentation. ( 29905579 )
2018
37
Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib. ( 29622884 )
2018
38
Reply to the Editor Regarding: Miranda RN, Clemens MW Letter to the Editor 2018 Apr 6 in Relation to: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesth Plast Surg, 2018. ( 29872907 )
2018
39
Anaplastic large cell lymphoma presenting as bilateral endobronchial tumor in a young boy. ( 29319039 )
2018
40
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
41
ALK-positive anaplastic large-cell lymphoma with primary bone involvement: A rare case and review of the literature. ( 30173234 )
2018
42
Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. ( 30407628 )
2018
43
CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. ( 30408331 )
2018
44
Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. ( 29242300 )
2018
45
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment. ( 29248547 )
2018
46
Response to "The Micromort Concept and its Applicability to Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Assessment". ( 29267890 )
2018
47
The Micromort Concept and its Applicability to Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Assessment. ( 29267944 )
2018
48
Diagnosis of anaplastic large-cell lymphoma in a dog using CD30 immunohistochemistry. ( 29455626 )
2018
49
Cytology of cerebrospinal fluid involvement in systemic anaplastic large-cell lymphoma. ( 29457294 )
2018
50
Commentary on: Breast Erythema in a Patient With Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report Discussing Cutaneous Manifestations. ( 29462290 )
2018

Variations for Anaplastic Large Cell Lymphoma

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CLU CSF1R IL9 JAK3 JUNB MCL1
2
Show member pathways
13.68 ALK CSF1R IL9 JAK3 JUNB MUC1
3
Show member pathways
13.21 ALK CSF1R IL9 JAK3 JUNB STAT3
4
Show member pathways
13.08 CSF1R IL9 JAK3 JUNB MCL1 MUC1
5 12.57 ALK CSF1R JAK3 STAT3 TFG TRAF1
6 12.09 CSF1R GZMB PAX5 TRAF1
7
Show member pathways
12 CSF1R IL9 JAK3 MCL1 PTPRC STAT3
8
Show member pathways
11.86 JAK3 JUNB STAT3
9 11.74 GZMB JAK3 JUNB PAX5 PTPRC STAT3
10
Show member pathways
11.66 JUNB MCL1 STAT3
11 11.65 CSF1R JAK3 PTPRC STAT3
12 11.62 GZMB IL9 PTPRC
13 11.41 JAK3 JUNB MCL1 MUC1 STAT3
14
Show member pathways
11.35 IL9 JAK3 STAT3
15
Show member pathways
11.29 CSF1R JAK3 STAT3
16 11.28 PAX5 PTPRC STAT3 TNFRSF8
17 11.26 JAK3 PTPRC STAT3
18 10.92 GZMB MCL1

GO Terms for Anaplastic Large Cell Lymphoma

Cellular components related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.44 ALK CLU CSF1R GZMB JAK3 MCL1

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.91 CLU GZMB MCL1 TNFSF8 TRAF1
2 negative regulation of apoptotic process GO:0043066 9.89 ALK CSF1R MCL1 NPM1 STAT3
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.55 ALK CLU NPM1 TNFRSF8 TRAF1
4 response to cytokine GO:0034097 9.5 JUNB MCL1 STAT3
5 interleukin-15-mediated signaling pathway GO:0035723 9.48 JAK3 STAT3
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.46 JAK3 STAT3
7 regulation of B cell receptor signaling pathway GO:0050855 9.43 PAX5 PTPRC
8 cytokine-mediated signaling pathway GO:0019221 9.43 CSF1R JAK3 JUNB MCL1 MUC1 STAT3
9 regulation of JAK-STAT cascade GO:0046425 9.4 JAK3 PTPRC
10 interleukin-21-mediated signaling pathway GO:0038114 9.37 JAK3 STAT3
11 regulation of extrinsic apoptotic signaling pathway GO:2001236 9.26 PTPRC TRAF1
12 interleukin-9-mediated signaling pathway GO:0038113 8.8 IL9 JAK3 STAT3

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CSF1R JAK3 STAT3

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....